Home › Glioblastoma › North Carolina
Glioblastoma clinical trials in North Carolina
26 studies for Glioblastoma are looking for participants at sites in North Carolina.
Cities in North Carolina
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
- Wake Forest University Health Sciences, Winston-Salem
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05432804A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Levine Children's Hospital- Pediatric Neuro-Oncology, Charlotte
RecruitingPhase 1/2
Up to age 25 · All sexes · Updated Sep 25, 2026 · NCT04094610Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
- East Carolina University, Greenville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07195591Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
- University of North Carolina, Chapel Hill
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT05902169Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas
- Wake Forest University, Winston-Salem
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT05139056Targeted Pediatric High-Grade Glioma Therapy
- Duke University Health System, Durham
RecruitingObservational study
12 Months – 39 Years · All sexes · Updated Sep 8, 2026 · NCT05839379Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Wake Forest University Health Sciences, Winston-Salem
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06860594Study of Olutasidenib and Temozolomide in HGG
- Duke University Health System, Durham
RecruitingPhase 2
Ages 12 to 39 · All sexes · Updated Sep 1, 2026 · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Duke Cancer Institute, Durham
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT05303519Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial
- Duke University Medical Center, Durham
- Wake Forest University Health Sciences, Winston-Salem
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT06319027BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma
- Duke University Medical Center, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT04903795A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment
- Duke University, Durham
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT05708352A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial
- Duke University, Durham
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT06069726A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- Comprehensive Cancer Center of Wake Forest*, Winston-Salem
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT03970447Lerapolturev (PVSRIPO) in GBM
- Duke University Medical Center, Durham
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 20, 2026 · NCT06177964DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Wake Forest University Health Sciences, Winston-Salem
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 1, 2026 · NCT06805305Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Duke University Health System, Durham
RecruitingEarly phase 1Healthy volunteers welcome
Ages 1 to 21 · All sexes · Updated Jun 29, 2026 · NCT06333899Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma
- Duke University Medical Center, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 4, 2026 · NCT04547777Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Duke University Health System, Durham
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated May 29, 2026 · NCT05843253Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
- Lineberger Comprehensive Cancer Center, Chapel Hill
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 22, 2026 · NCT05366179Key Longitudinal Associations With Risk and Glioblastoma Outcomes
- Duke University, Durham
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jan 20, 2026 · NCT06625684SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chapel Hill
- Massive Bio SYNERGY-AI site, Winston-Salem
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774D2C7-IT + 2141-V11 Combination Post-resection in rGBM
- Duke University Medical Center, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 23, 2025 · NCT06455605D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients
- Duke University Medical Center, Durham
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 6, 2025 · NCT05734560APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
- University of North Carolina, Chapel Hill
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 27, 2025 · NCT03175224Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
- Duke University, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 25, 2025 · NCT05879367From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.